Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05453396

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a chemotherapy drug, called tesirine. Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them.

Detailed description

OUTLINE: Patients receive loncastuximab tesirine intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 5 years.

Conditions

Interventions

TypeNameDescription
BIOLOGICALLoncastuximab TesirineGiven IV

Timeline

Start date
2023-08-07
Primary completion
2026-12-15
Completion
2027-07-06
First posted
2022-07-12
Last updated
2025-10-16

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05453396. Inclusion in this directory is not an endorsement.